CN111542539B - 通过cd39/cd73轴恢复t细胞活性 - Google Patents

通过cd39/cd73轴恢复t细胞活性 Download PDF

Info

Publication number
CN111542539B
CN111542539B CN201880064186.3A CN201880064186A CN111542539B CN 111542539 B CN111542539 B CN 111542539B CN 201880064186 A CN201880064186 A CN 201880064186A CN 111542539 B CN111542539 B CN 111542539B
Authority
CN
China
Prior art keywords
antibody
group
antibodies
amino acid
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880064186.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111542539A (zh
Inventor
S·尚特克斯
N·戈尔丁
C·帕图雷
I·普罗特
B·罗西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN111542539A publication Critical patent/CN111542539A/zh
Application granted granted Critical
Publication of CN111542539B publication Critical patent/CN111542539B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880064186.3A 2017-10-06 2018-10-05 通过cd39/cd73轴恢复t细胞活性 Active CN111542539B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762568812P 2017-10-06 2017-10-06
US62/568,812 2017-10-06
US201862686143P 2018-06-18 2018-06-18
US62/686,143 2018-06-18
PCT/EP2018/077217 WO2019068907A1 (en) 2017-10-06 2018-10-05 RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73

Publications (2)

Publication Number Publication Date
CN111542539A CN111542539A (zh) 2020-08-14
CN111542539B true CN111542539B (zh) 2023-10-20

Family

ID=63799006

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880064186.3A Active CN111542539B (zh) 2017-10-06 2018-10-05 通过cd39/cd73轴恢复t细胞活性

Country Status (11)

Country Link
US (2) US20190218308A1 (https=)
EP (1) EP3692068B1 (https=)
JP (1) JP7274469B2 (https=)
KR (1) KR102710877B1 (https=)
CN (1) CN111542539B (https=)
AU (1) AU2018346447B2 (https=)
BR (1) BR112020006809A2 (https=)
CA (1) CA3074588A1 (https=)
IL (1) IL273414B1 (https=)
SG (1) SG11202002192QA (https=)
WO (1) WO2019068907A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2238170B1 (en) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
GB2545676A (en) * 2015-12-21 2017-06-28 Dublin Inst Of Tech Prediction of therapeutic response using vibrational spectroscopy
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
MY202018A (en) 2017-07-31 2024-03-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP3788079A4 (en) 2018-05-03 2022-12-21 Shanghai Epimab Biotherapeutics Co., Ltd. ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF
DK3807316T3 (da) 2018-06-18 2024-07-29 Innate Pharma Sammensætninger og fremgangsmåder til behandling af cancer
MX2021012769A (es) 2019-04-23 2021-11-18 Innate Pharma Anticuerpos bloqueadores cd73.
NZ781538A (en) 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
JP7471016B2 (ja) * 2019-08-21 2024-04-19 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド 抗ｃｄ７３抗体およびその適用
JP7727387B2 (ja) * 2019-08-27 2025-08-21 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
CN114651013B (zh) 2019-11-05 2025-03-14 北京加科思新药研发有限公司 对cd39具有特异性的结合分子及其用途
CA3165384A1 (en) * 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
CN114106160A (zh) * 2020-08-28 2022-03-01 安源医药科技（上海）有限公司 抗SARS-CoV-2病毒单克隆抗体及应用
US20220133902A1 (en) * 2020-11-04 2022-05-05 Heidelberg Pharma Research Gmbh Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy
CA3211501A1 (en) * 2021-02-19 2022-08-25 Janssen Biotech, Inc. Materials and methods for targeting regulatory t cells for enhancing immune surveillance
CN117241832A (zh) 2021-03-19 2023-12-15 海德堡医药研究有限责任公司 B淋巴细胞特异性的鹅膏毒素抗体缀合物
MX2024010646A (es) 2022-03-03 2024-09-19 Arcus Biosciences Inc Anticuerpos anti-cd39 y uso de los mismos.
US20250361314A1 (en) * 2022-06-08 2025-11-27 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd39/cd73 bispecific antigen binding protein and use thereof
EP4683650A2 (en) * 2023-03-21 2026-01-28 Beam Therapeutics Inc. Immunosuppressant-resistant modified allogeneic modified immune cells and methods for use thereof
CN120992939B (zh) * 2025-10-27 2025-12-26 苏州旭光科星抗体生物科技有限公司 一种可溶性cd39蛋白含量检测试剂盒及其应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
WO2009095478A1 (en) * 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
CN104244977A (zh) * 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CN106852149A (zh) * 2014-10-10 2017-06-13 依奈特制药公司 Cd73阻断
CN110382544A (zh) * 2017-03-16 2019-10-25 先天制药公司 用于治疗癌症的组合物和方法
CN111372606A (zh) * 2017-11-15 2020-07-03 先天制药公司 增强atp释放作用
CN113784981A (zh) * 2019-04-23 2021-12-10 先天制药公司 Cd73阻断抗体
CN114127121A (zh) * 2019-08-12 2022-03-01 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
US8865653B2 (en) * 2010-04-22 2014-10-21 Institut Gustave Roussy Method of treatment for immunogenic treatment resistant cancer
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MA39986A (fr) 2014-04-25 2017-03-01 Vitae Pharmaceuticals Inc Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
GB2538120A (en) * 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
CA3005986A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CN114805575B (zh) 2015-12-09 2024-07-23 科尔沃斯制药股份有限公司 人源化抗cd73抗体
WO2017120508A1 (en) 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2018094148A1 (en) 2016-11-18 2018-05-24 Arcus Biosciences, Inc. Inhibitors of cd73-mediated immunosuppression

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387645B1 (en) * 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
WO2009095478A1 (en) * 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
CN104244977A (zh) * 2012-02-07 2014-12-24 先天制药公司 Mica结合剂
CN106852149A (zh) * 2014-10-10 2017-06-13 依奈特制药公司 Cd73阻断
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
CN110382544A (zh) * 2017-03-16 2019-10-25 先天制药公司 用于治疗癌症的组合物和方法
CN111372606A (zh) * 2017-11-15 2020-07-03 先天制药公司 增强atp释放作用
CN113784981A (zh) * 2019-04-23 2021-12-10 先天制药公司 Cd73阻断抗体
CN114127121A (zh) * 2019-08-12 2022-03-01 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion;Sebastian Fm Häusler;《American Journal of translational research》;第6卷(第2期);第129-139页 *
CD39和CD73在CD4+CD25highFoxp3+调节性T细胞发挥免疫抑制功能中的作用研究;韩凌等;《现代免疫学》(第2期);第101-106页 *
Targeting the CD73-adenosine axis in immuno-oncology;DavidAllard;《Immunology Letters》;第5卷;第31-39页 *

Also Published As

Publication number Publication date
KR102710877B1 (ko) 2024-09-26
KR20200060471A (ko) 2020-05-29
EP3692068B1 (en) 2022-12-07
JP7274469B2 (ja) 2023-05-16
BR112020006809A2 (pt) 2020-10-06
IL273414A (en) 2020-05-31
WO2019068907A1 (en) 2019-04-11
IL273414B1 (en) 2026-04-01
AU2018346447A1 (en) 2020-03-19
CN111542539A (zh) 2020-08-14
US20190218308A1 (en) 2019-07-18
AU2018346447B2 (en) 2025-06-19
EP3692068A1 (en) 2020-08-12
US20230099801A1 (en) 2023-03-30
SG11202002192QA (en) 2020-04-29
CA3074588A1 (en) 2019-04-11
JP2020536109A (ja) 2020-12-10

Similar Documents

Publication Publication Date Title
CN111542539B (zh) 通过cd39/cd73轴恢复t细胞活性
JP7132981B2 (ja) Ｃｄ７３遮断
CN110382544B (zh) 用于治疗癌症的组合物和方法
CN111372606B (zh) 增强atp释放作用
US11130817B2 (en) CD73 blocking agents
CN112334486B (zh) 用于治疗癌症的组合物和方法
WO2016131950A1 (en) Cd73 blockade
US20180030144A1 (en) Cd73 blockade
EA044293B1 (ru) Восстановление активности t-клеток посредством системы cd39/cd73
HK40040395A (en) Compositions and methods for treating cancer
HK40040395B (zh) 用於治疗癌症的组合物和方法
BR112017006464B1 (pt) Anticorpo isolado, composição farmacêutica, uso de um anticorpo e anticorpo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant